Canine models for human genetic neurodegenerative diseases

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 24, Issue 5, 2000, Pages 811-823

  Barsoum, Suzy C ^a   Callahan, Heather M ^b   Robinson, Kelly ^a   Chang, Patricia L ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer disease; Cognitive tests; Gene therapy; Lysosomal storage disease; Mucopolysaccharidosis

Indexed keywords

ALZHEIMER DISEASE; ANIMAL MODEL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DOG; GENETIC DISORDER; LYSOSOME STORAGE DISEASE; MUCOPOLYSACCHARIDOSIS; NONHUMAN; REVIEW;

EID: 0033890747     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(00)00108-1     Document Type: Article

References (62)

1. Functional recovery in Hemiparkinsonian primates transplanted with polymer-encapsulated PC12 cells
2. Intrathecal delivery of CnTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
3. Long-term effects of bone marrow transplantion in dogs with mucopolysaccharidosis I
4. The in vivo delivery of heterologous proteins by microencapsulated recombinant cells
5. Persistence in muscle of an adenoviral vector that lacks all viral genes
6. Accelerated hereditary canine spinal muscular atrophy (HCSMA)
7. Pathology of motor neurons in accelerated hereditary canine spinal muscular atrophy
8. Changes in neuronal size and neurotransmitter marker in hereditary canine spinal muscular atrophy
9. Changes in size of motor axons in hereditary canine spinal muscular atrophy
10. The canine as an animal model of human aging and dementia
11. β-amyloid accumulation correlates with cognitive dysfunction in the aged canine
12. Transfer of genes to humans: Early lessons and obstacles to success
13. Batten's disease: Failure of allogeneic bone marrow transplantation to arrest disease progression in a canine model
14. Growth factor-induced neurite growth in primary neuronal cultures of dogs with neuronal ceroid lipofuscinosis
15. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver
16. CNS delivery by retrograde transport of recombinant replication-defective adenoviruses
17. Cardiovascular changes after bone marrow transplantation in dogs with mucopolysaccharidosis I
18. Follow up of nine patients with Hurler syndrome after bone marrow transplantation
19. β-Glucuronidase deficiency in a dog: A model of human mucopolysaccharidosis VII
20. High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5
21. Role of subunit-9 of mitochondrial ATP synthase in Batten disease
22. A packaging cell line for lentivirus vectors
23. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I
24. Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders
25. The English setter with ceroid-lipofuscinosis: A suitable model for the juvenile type of ceroid-lipofuscinosis in humans
26. Use of herpes simplex virus type I for transgene expression within the nervous system
27. Apoptosis as the mechanism of neurodegeneration in Batten's disease
28. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine α-L-iduronidase deficiency
29. Gene therapy for canine α-L-iduronidase deficiency: Hematopoietic progenitors result in engraftment but not amelioration of disease
30. Encapsulated cells as therapy
31. The mucopolysaccharide storate diseases
32. Cognitive functions and aging in the dog: Acquisition of nonspatial visual tasks
33. Mucopolysaccharidoses
34. The basic science of gene therapy
35. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
36. Delivery of gene products to the central nervous system by grafting retrovirally engineered neuronal and non-neuronal cells
37. Gene therapy for Amyotrophic Lateral Sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF
38. Gene therapy in the central nervous system: Direct versus indirect gene delivery
39. Adenoviral vectors as functional retrograde neuronal tracers
40. Autosomal dominant inheritance of hereditary canine spinal muscular atrophy
41. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
42. Modified Bielschowsky and immunohistochemical studies on senile laques in aged dogs
43. Canine α-L-iduronidase deficiency: A model of mucopolysaccharidosis I
44. Morphologic and biochemical studies of canine mucopolysaccharidosis I
45. Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system
46. Long-term neurological effects of bone marrow transplantation in a canine lysosomal storage disease
47. Radiographic findings in a canine model of mucopolysaccharidosis I changes associated with bone marrow transplantation
48. Lectin histochemical evaluation of neuronal glycosaminglycan content following bone marrow transplantation of dogs with MPS I
49. Enzyme replacement in a canine model of Hurler syndrome
50. Myoblast gene therapy in canine mucopolysaccharidosis I: Abrogation by an immune response to α-L-iduronidase
51. Gene therapy for neurologic disease
52. Ceroid lipofuscinosis in the border Collie dog: Retinal lesions in an animal model of juvenile Batten disease
53. Alterations in neuron morphology in mucopolysaccharidosis type I. A Golgi study
54. Gene therapy for cerebrovascular disease
55. Clinical and morphologic features of mucopolysaccharidosis type II in a dog: Naturally occurring model of Hunter syndrome
56. An encapsulated dopamine-releasing polymer alleviates experimental Parkinsonism in rats
57. Immune responses to adenovirus vectors in the nervous system
58. Immune responses to virusts: Practical implications for the use of viruses as vectors for experimental and clinical gene therapy
59. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis